New DNA Test Could Detect Several Cancers Simultaneously

As the latest innovations are cropping up daily, the health sector is also enjoying those benefits. Several methods of testing and detecting various diseases are being developed day by day. For instance, identifying conditions like cancer at the early stages is growing as the day goes by, and recent discoveries show that any disease can now be detected at its most initial stage.

Detecting Cancer Through DNA Evaluation of Fragments for Early Interception Packaging

A novel test has been discovered recently which can detect different kinds of cancer from blood samples. Researchers have developed the new method at the Johns Hopkins Cancer Center, which relies on original DNA packaging. The technique does not rely on tumors for it to detect the presence of cancer cells.

The DNA evaluation of fragments for early interception (“DELFI”) method works by analyzing cell-free DNA (cfDNA) in a patient’s bloodstream. It also uses artificial intelligence in identifying the abnormal DNA structures floating in the blood. In normal cases, the DNA is always packaged in a healthy cell nucleus in a well-organized way. However, if a cell is diagnosed with cancer, the DNA packaging is still disorganized compared to a healthy cell. The disorganization leads to their release into the bloodstream in a very unsystematic way.

DELFI can detect abnormalities in the amount and size of the DNA based on its packaging. Due to these abnormalities, the test identifies the presence of cancer faster and in an easy way. The current analysis used in detecting cancer works by either detecting methylation or mutation. Methylation is a process involving chemical reactions in which methyl groups are added to the DNA, which rarely occurs.

Furthermore, the efficiency of DELFI has been tested by using blood samples from cancer and non-cancer patients. Its effectiveness in detecting cancer was found to be between 55%-99% depending on the type of cancer. The method was used to test lung, pancreatic, ovarian, gastric, breast, bile duct, and colorectal cancers. Besides, DELFI was also able to identify the tissues from which lung, chest, and colon cancers originated from.

According to one of the researchers, the potentiality of DNA Evaluation of Fragments for Early Interception in detecting cancer at its early stages is encouraging. The researchers are working closely with other relevant bodies to make this test available to cancer patients quickly. Biomedical companies like DarioHealth Corp. (NASDAQ: DRIO) are likely to follow this research closely as it could have huge potential in the industry.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050